syndesi therapeutics pipeline

About Syndesi Therapeutics Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. PATIENTS & FAMILIES. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. OUR PIPELINE JOIN US TODAY The biotech notes that disruption of the synaptic connectivity is found in Alzheimers and other types of dementia. Fountain Healthcare Partners (www.fh-partners.com) is a life science focused venture capital fund with 176 million ($200 million) under management. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. AbbVies neuroscience drug prospects are from its partnership with Calico Life Sciences, a firm founded by Google parent company Alphabet. There is a major unmet need for new therapies that can . Ferrous(II) glycine sulphate complex (Ferro Sanol), Plain language summaries of study results, Access to Patient-Level Clinical Study Data, Plain Language Summaries of research results, Registration and Results Reporting on Public Registries, Cimzia - Axial spondyloarthritis (axSpA), Privacy Policy for Healthcare Professionals, Syndesi Therapeutics to leverage UCBs expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism, Series A financing of 17 M from a syndicate of Belgian and international investors. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic . Syndesi Therapeutics was established to develop a series of novel, pro-cognitive small molecule SV2A modulators licensed from UCB. "I am delighted with the closing of this deal. //-->. The firm deploys the majority of its capital in Europe, with the balance in the United States. Do not sell my information, Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug, How To Create Digital Health Apps That Serve as Useful Tools (Not Unnecessary Work), Why Digital Health Collaborations Are the Future of Medtech, Rubiuss New Cell Therapy Strategy Runs Out of Time & Money; Workforce Is Cut by 82%, Startup Founded by Brown Undergrads Raises $14M to Improve Care for Vulnerable Seniors, AMA: CMS 2023 Physician Fee Schedule Would Create Financial Instability, Carta Healthcare Rakes in $20M with Hopes of Selling its Tech to More Hospitals, CVS, Walgreens Will Pay $10 Billion Total To Settle Opioid-Related Lawsuits. COPENHAGEN, Denmark, March 1, 2022 /PRNewswire/ -- Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ('Syndesi'). Syndesi Therapeutics edit_note Submit Changes Louvain-la-Neuve, Belgium http://www.syndesitherapeutics.com/ Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. The VIVES Louvain Technology Fund (www.vivesfund.com) is a multi-sector technology fund which invests in the spin-offs of the Universit catholique de Louvain (UCL) and start-ups in Belgium and neighboring countries. Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa; August 26 2022 | News No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak; August 24 2022 | News Appointments and advancements for Aug. 24, 2022; August 24 2022 | Press Releases This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders. In June last year, AbbVie exercised an exclusive option for the acquisition of TeneoOne, a Teneobiosubsidiary. North Chicago, Illinois-based AbbVie announced Tuesday that it paid $130 million up front to acquire Syndesi Therapeutics. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the worlds premier life science institutes. Prilenia Therapeutics. Connecting Health Systems and Life Science Researchers To Maximize the Potential of Real-world Evidence. SRIW Socit Rgionale d'Investissement de Wallonie (www.sriw.be) provides equity and/or debt to companies that generate added value and employment in Wallonia. About Syndesi Therapeutics Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Back to companies Read more Press releases Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. //